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ABSTRACT 
Objective: The objective of this study was to investigate differences in pharmacokinetic patterns of immediate release tablet (IR) and compression 
coated tablet (CCT) of lornoxicam, proposed for the chronotherapeutic treatment of rheumatoid arthritis.  
Methods: The dosage forms were administered to two groups of white New Zealand rabbits (n=3), and the plasma drug levels were measured by 
liquid chromatography-tandem mass spectrometry (LC-MS/MS). Pharmacokinetic parameters like maximum concentration (Cmax), time is taken to 
reach maximum concentration (Tmax), area under the curve (AUC), elimination half-life (t1/2
Results: In the case of IR tablets, the drug was detected within 15 min after oral administration and a Cmax of 1269.57±4.04 ng/ml were attained at 
2±0.15 h. With CCT, the drug was detected only after 5 h and a Cmax of 1279.24±12.76 ng/ml were attained at 8±0.10 h. The CCT showed maximum 
drug release at the eighth hour in comparison to IR tablet which showed maximum release at the second hour of study.  
) and Mean Residence Time (MRT) were determined. 
Conclusion: The predominant lag time prior to drug release from CCT is an indication that it is consistent with the requirements of 
chronopharmaceutical drug delivery. The results suggest that the compression coated tablet is a promising approach for chronotherapeutic 
management of rheumatoid arthritis. 
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Chronotherapeutics refers to a treatment method that is in 
accordance with a patient’s daily, monthly, seasonal or yearly 
biological clock, in order to achieve maximum therapeutic benefits 
and minimal adverse effects. Chronotherapeutic drug delivery 
systems (ChrDDs) with a preset lag time are helpful for patients 
suffering from allergic rhinitis, rheumatoid arthritis (RA) and 
related disorders, asthma, cancer, cardiovascular diseases and 
peptic ulcer disease as the drug is released at a predetermined time 
and the maximum concentration (Cmax
Rheumatoid arthritis (RA) is a chronic, autoimmune inflammatory 
disease characterized by joint swelling, tenderness and progressive 
destruction of synovial joints, leading to severe disability and 
premature mortality [4]. Morning stiffness that lasts for hours in one 
or more of the smaller joints is a common early sign of RA. 
Chronopharmacotherapy for RA has been recommended to ensure 
that the highest blood levels of the drug coincide with the incidence of 
pain and stiffness. Compression coated tablets (CCT) are dosage forms 
consisting of an inner immediate release core tablet embedded in an 
outer layer made of a hydrophilic or hydrophobic polymer or a 
combination of both. The outer layer disintegrates or dissolves slowly 
to release the drug after a predetermined lag time [5, 6]. 
) of the drug will be reached 
when the symptoms of the disease are at its peak [1-3].  
This technique is simple, economical and eliminates the need for a 
tedious and time-consuming granulation or coating processes. It can be 
used to physically separate two incompatible drugs within the same 
dosage form and also improves the stability of the drug by protecting it 
from moisture [7]. Current drugs that are available in the market are 
conventional film-coated, and enteric coated tablets of NSAIDs and these 
dosage forms are to be taken twice or thrice a day post meals. This does 
not reduce the pain and stiffness of RA patients, especially in the early 
morning hours. This necessitates the present study on the development 
of compression coated tablets and to study differences in the 
pharmacokinetic patterns of a compression coated tablet and an 
immediate release tablet (conventional), both containing the same dose 
of lornoxicam.  
MATERIALS AND METHODS 
Materials 
Lornoxicam was a generous gift sample from Lifecare formulations, 
Puducherry, India. Ethyl acetate-AR grade, methanol-HPLC grade, and 
Milli-Q water-HPLC grade were procured from SD fine chemicals ltd, 
India. 
The study protocols were approved by the institutional animal 
ethics committee (IAEC) of M. S Ramaiah College of Pharmacy, 
Bangalore, India (CPCSEA approval no: 220/PO/abc/2000/CPCSEA 
and renewal approval no: XVIII/MSRFPH/P-10/8.2.17) 
Methods 
a) Dosage forms 
Immediate release core tablets containing 8 mg lornoxicam and 
compression coated with an interpenetrating polymer network 
(IPN) of chitosan-poly (acrylamide) were chosen as dosage forms for 
the study. 
b) Animals 
The pharmacokinetic study [8] was performed using New Zealand 
white rabbits (2.5-3 kg) of either sex. The animals were housed in 
polycarbonate cages in a room maintained under constant 
environmental conditions (22±1 °C, 50±5% RH). Food and water 
were given ad libitum. Six rabbits were divided into two groups (A 
and B); containing three rabbits each. The numbers of animals were 
selected as per the recommendations of the IAEC. Group, I rabbits 
was administered immediate release core tablets (IR) of lornoxicam, 
and group II rabbits were administered compression coated tablets 
(CCT) of lornoxicam [9-13].  
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The study was conducted in a crossover design with a washout 
period of three weeks in between the two experiments. The 
dosage forms were administered using sterile internal stomach 
pumps. 
c) Dose fixation 
The human dose of lornoxicam is 8 mg and the dose given to each rabbit 
was adjusted to 0.4 mg/kg according to Paget and Barnes [14].  
d) Blood sampling 
The rabbits were fasted overnight for 12 h prior to the study. The 
tablet was administered using sterile feeding tubes. The animals were 
fed 4 h after drug dosing and had free access to water throughout the 
study period. 2 ml of blood samples were collected through the 
marginal ear vein into heparinized tubes at predetermined intervals of 
0, 15, 30, 60, 120, 240, 360, 480 and 600 min postdose. The plasma 
was separated immediately by centrifugation at 10000 rpm for 5 min 
and maintained at-20 °C until further analysis.  
e) Analytical method development for determination of 
lornoxicam in rabbit plasma 
Drug levels in the plasma were analyzed by LC-MS/MS [8]. 
Preparation of lornoxicam standard stock solution 
10 mg of accurately weighed lornoxicam working standard was 
transferred into a 10 ml volumetric flask, dissolved in methanol and 
the volume was made with methanol to produce a stock solution of 
strength 1000 µg/ml. This solution was stored in a refrigerator at 2-
8 °C. Working internal standard solutions in the concentration range 
5.0-2200.00 ng/ml were prepared by suitably diluting the stock 
solution with methanol afresh before use. 
Spiking of blank plasma samples 
180 µl of drug-free rabbit plasma was spiked with 20 µl of 
lornoxicam standard calibrants (5.0-2137.45 ng/ml), separately 
extracted with 800 µl ethyl acetate and analyzed by LC-MS. The 
response obtained for different levels of calibrants was analyzed by 
linear regression and regression equation obtained was used for 
estimating lornoxicam concentration in unknown rabbit plasma 
samples processed similarly.  
Regression equation used for calculating lornoxicam in unknown 
samples:  
Y=54.436 X+888.54,  
Where Y = peak area of lornoxicam, and  
X is the concentration of lornoxicam in ng/ml of plasma samples. 
Preparation of plasma samples 
All the frozen rabbit plasma samples were thawed at room 
temperature and vortexed to ensure uniform mixing of contents. 
Lornoxicam was selectively isolated from 200 µl plasma by liquid-
liquid extraction using ethyl acetate as the extraction solvent. 200 µl 
plasma was vortexed with 800 µl ethyl acetate for 5 min at 2500 
rpm. The mixture was centrifuged at 12000 rpm for 5 min and the 
supernatant collected. The extract was then evaporated to dryness 
under a stream of nitrogen followed by reconstitution with 100 µl of 
mobile phase (acetonitrile: 2 mmol ammonium formate buffer in the 
ratio 70:30 v/v). 10 µl of the prepared sample was then injected into 
the LC-MS/MS system and analyzed for drug content. 
Instrumentation and chromatographic conditions 
Shimadzu PROMINENCE LC-20AT series HPLC was used. The 
equipment consisted of an AGILENT ZORBAX XB-C18 column (5 µm 
particle size; 50 mm *4.6 I. D). The mobile phase used was 
acetonitrile: 2 mmol ammonium formate buffer (70:30 v/v) and was 
run at a flow rate of 0.4 ml/min. The temperature of the column 
oven was maintained at 45 °C and that of the autosampler at 10 °C. 
The injection volume was 10 µl and the total run time was 10 min.  
LC-MS/MS analysis was performed on SCIEX series API 4000 triple, 
quadruple mass spectrometer equipped with electrospray ionization 
(ESI) interface with turbo ion spray. Positive ions were measured in 
mode (ionspray voltage: 5300 KV, declustering potential: 86.50 eV, 
entrance potential: 12.50 eV, temperature of source: 450 °C). The 
mass spectrometer was programmed to monitor the precursor ion 
[M+H] of lornoxicam at m/z 372 and fragment ion [M+H]+at m/z 
121.60 
f) Data analysis 
Pharmacokinetic parameters like maximum concentration (Cmax), 
time taken to reach maximum concentration (Tmax), area under the 
curve (AUC0-24), area under the first moment curve (AUMC0-24), 
elimination half-life (t1/2
A rapid and selective analytical method was developed for the 
quantitative analysis of lornoxicam in rabbit plasma. A retention and 
separation of lornoxicam were obtained by using acetonitrile: 2 
mmol ammonium formate buffer (70:30 v/v) as the mobile phase. 
The correlation coefficient for lornoxicam over the concentration 
range of 5.0 ng/ml–2137.45 ng/ml was found to be 0. 9984. The 
average slope and intercept of regression equations were 54.43 and 
888.5 respectively (table 1 and fig. 1). 
) and mean residence time (MRT) were 
determined by Kinetica 5.0 (Thermofisher Scientific, PK/PD 
software, USA) for each sample.  
RESULTS AND DISCUSSION 
The primary goal for developing any dosage form is to deliver the 
required concentration of an active drug substance to the site of 
action and to achieve optimum efficacy. The ability of compression 
coated tablets as a drug delivery system to release drugs in a 
predetermined time-release manner was investigated in New 
Zealand white rabbits. The core and compression coated tablets of 
lornoxicam, prepared and evaluated under laboratory conditions 
were considered for pharmacokinetic studies. 
 
 
Fig. 1: The calibration curve of lornoxicam in rabbit plasma 
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Table 1: Data for standard calibration curve of lornoxicam in rabbit plasma 







*Each value is represented as a mean±standard deviation of three observations (n=3) 
 
The LC-MS/MS method was found to satisfy the requirement of 
routine analyses as it had a short run time (3 min). The MS 
optimization was performed by direct injection of lornoxicam into 
the mass spectrometer. The mass parameters were optimized to 
obtain better ionization of lornoxicam molecules. The full scan 
spectrum [15] was dominated by protonated molecule m/z 372.00 
for lornoxicam and the major fragment ions observed in the product 
spectrum was at m/z 121.60 (fig. 2-3). 
  
 
Fig. 2: Mass scan of lornoxicam standard 
 
 
Fig. 3: Product ion spectrum of lornoxicam standard 
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Fig. 4: Single ion monitoring (SIM) chromatogram of a) blank plasma sample and b) lornoxicam standard (concentration-2137.45 ng/ml) 
 
The retention time obtained for lornoxicam was 1.24 min. The 
representative chromatograms of blank plasma and plasma samples 
spiked with lornoxicam are shown in fig. 4. 
The developed LC-MS/MS method was successfully applied for 
pharmacokinetic study in rabbits. In the case of IR, the drug was 
detected within 15 min after its oral administration in rabbits. The 
chromatograms of plasma samples withdrawn at different intervals 
of time for IR are shown in fig. 5. 
  
 
Fig. 5: LC-MS chromatogram of IR–a) at 15 min b) 30 min c) 1 h d) 2 h 
 
In the case of CCT, the drug was detected only after 5 h. This 
indicates that there was a predominant lag time before the drug 
release. The chromatograms of plasma samples withdrawn at 
different intervals of time for CCT are shown in fig. 6 [16]. 
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Fig. 6: LC-MS chromatogram of CCT–a) at 0 h b) 2 h c) 4 h d) 6 h e) 8 h 
 
The drug absorption was rapid in the case of IR, i.e., a Cmax of 
1269.57±4.04 ng/ml was attained at a Tmax of 2±0.15 h (120 
min) h. In CCT, a Cmax of 1279.24±12.76 ng/ml was attained at a 
Tmax of 8±0.10 h (480 min), but no drug was detected till 5 h in 
all the three rabbits, indicating a similar correlation with in vitro 
release. The AUC 0-24 
MRT is defined as the average time spent by the drug in the body 
and can be used to compare the in vivo performance of different 
dosage forms. The difference in MRT values (3.45 and 9.12 h for IR 
and CCT respectively) is an indication of the pulsatile release pattern 
of compression coated tablet. The other pharmacokinetic 
parameters [9] determined were AUMCfor animals administered IR was found to be 




, t ½ and Ke (table 2 and 
fig. 7). The results of the in vivo studies indicated that drug release 
from CCT took place only after the desired lag time. 
Table 2: Summary of pharmacokinetic parameters of all the groups 
Pharmacokinetic parameters Group I (Core tablets of lornoxicam)* Group II (Compression coated tablets of lornoxicam)* 
Cmax 1269.57±12.89 (ng/ml) 1279.24±12.76 
Tmax(h) 2±0.15 8±0.10 
Lag time (h) 0±0 5±0.10 
AUC0-24 4503.59±42.0 (ng/mlh) 4598.36±74.1 
AUMC0-24 (ng/ml * [h]2 15552.4±261.92 ) 41968.23±808.25 
t ½ (h) 1.43±0.01 1.53±0.025 
Ke (h-1 0.48±0.005 ) 0.45±0.005 
MRT (h) 3.45±0.036 9.12±0.03 
* Each value is represented as a mean±standard deviation of three observations (n=3) 
 
 
Fig. 7: Plasma drug concentration-time curves for pharmacokinetic study in rabbits, *All points are presented as mean±SD of observations (n=3) 
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CONCLUSION 
A rapid and selective LC-MS/MS method was developed for the 
quantitative analysis of lornoxicam in rabbit plasma. An acceptable 
retention and separation of lornoxicam were obtained by using 
acetonitrile: 2 mmol ammonium formate buffer (70:30 v/v) as the 
mobile phase. The developed method was found to be highly 
sensitive and suitable for the detection of lornoxicam in plasma in 
concentrations as low as 5 ng/ml. The results of the 
pharmacokinetic studies indicated that drug release from 
compression coated tablet took place only after a lag time of 5 h. 
Thus, drug release, consistent with requirements for 
chronopharmaceutical drug delivery, was achieved from the 
compression coated tablet. Thus the formulation can be considered 
as one of the promising tools for chronotherapeutic management of 
rheumatoid arthritis with improved patient compliance. 
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